IMVT ▼ -6.2% - Immunovant, Inc. $IMVT - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant shares fell 6.2% following the company's announcement of topline results from its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus. The market's negative reaction suggests investors viewed the trial data as disappointing or insufficient to support advancement of the candidate, though the specific efficacy or safety findings were not detailed in the headline. 23-SEP-2026 07:00 AM ET